GlaxoSmithKline (GSK) is dedicated to helping people live longer, healthier lives. As a world-leading research-based pharmaceutical company, we spend billions of dollars and many years in the development of new medicines, because that’s what it takes. We’re also dedicated to helping patients afford the medicines they need, because it's the right thing to do.

GSK is currently developing medicines to treat diseases ranging from cancer to cardiovascular disease to respiratory illnesses. In addition to more than 50 prescription medicines and vaccines already on the market, GSK has more than 140 medicines and vaccines in clinical development.

For example, every second, more than 30 doses of our vaccines are distributed to those in need. Every minute, more than 1,100 prescriptions are written for our products. New medicines are important to you and to us. In fact, we invest $4.3 billion annually for the research and development of new medications.

At GSK, we have 106,000 employees worldwide, 23,000 in the US. Our global quest is to improve the quality of human life by enabling people to do more, feel better, and live longer.

GSK has more than 1,200 products ranging from tablets and toothpaste to inhalers and complex capsules.

GSK PHARMACEUTICAL THERAPEUTIC AREAS include:

• Asthma
• Cancer
• Cardiovascular
• Chronic Obstructive Pulmonary Disease (COPD)
• Depression
• Diabetes
• HIV/AIDS
• Infectious Disease
• Migraine
• Urology2

GSK VACCINES include:

• DPT
• Hepatitis A
• Hepatitis B
• MMR
• Polio2

GSK CONSUMER HEALTHCARE AREAS include:

• Gastrointestinal
• Nicotine Replacement
• Oral Healthcare

GSK is committed to improving access to medicines. In the US, GSK offers two programs: Bridges to Access, which provides free medicines to eligible patients, and Commitment to Access, a special oncology medicine program. These programs are among the most generous patient assistance programs offered by any company in the pharmaceutical industry and offer a short-term solution for patients without prescription drug coverage. In addition, GSK led the pharmaceutical industry two years ago when it launched the Orange Card for lower-income Medicare participants. The Orange Card is for seniors and the disabled enrolled in Medicare who are currently without public or private insurance coverage for prescription medicines and have incomes below $30,000 for a single and $40,000 for a couple (roughly 300% of the federal poverty level).

In 2002, GSK donated $375 million to global community programs, including cash and product donations, to help people in need around the world.

GSK works with a variety of national and international non-governmental organizations such as the World Health Organization, UNICEF and UNAIDS, the American Association of Diabetes Educators, the Epilepsy Association, the American Family Practice Association, and the American Herpes Foundation to help improve access to medicines.

The mosquito-borne disease lymphatic filariasis (LF or elephantiasis) is one of the world’s most disabling diseases. We are a committed, active member of the Global Alliance to Eliminate Lymphatic Filariasis. In 2002, the fourth year of the program, GSK donated 66 million tablets to help people at risk in 31 countries.

We're proud of who we are and what we do, and proud to share our story.

Because we're not just helping today's patients, but tomorrow's as well.

Today's medicines finance tomorrow's miracles.

Visit GlaxoSmithKline